Daniel Lang

Farallon Capital Management LLC (Farallon) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1986 and is a wholly-owned subsidiary of Farallon Capital Management LP. Farallon provides administrative services and discretionary investment management services to private investment funds, the securities of which are offered to investors on a private placement basis; and to separately managed accounts for institutions such as endowments, foundations, charitable organizations and state and municipal government entities.

RS Investment Management Co. LLC (also known as RS Investments) is an investment advisor and mutual fund manager headquartered in San Francisco, California. Founded in 1986, the firm was acquired by Victory Capital Management, Inc. from The Guardian Life Insurance Co. of America in July 2016. They operate as an independent franchise within Victory Capital's multi-boutique model. Each of the teams within the RS franchise continues to operate autonomously. RS Investments provides investment advisory services to mutual funds, institutions, private pooled investment vehicles, and high net-worth individuals.

The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY.

Victory Capital Management, Inc. (Investment Management) (Victory Capital-IM) is the investment management division of Victory Capital Management, Inc., a financial services company headquartered in San Antonio, Texas. The firm was founded in 1894 and formerly known as Key Asset Management, Inc. They are an indirect, wholly owned subsidiary of Victory Capital Holdings, Inc. (NASDAQ: VCTR). Victory Capital-IM provides specialized investment strategies to institutions, intermediaries, retirement platforms and individual investors.

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.